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Bacterial artiﬁcial chromosome (BAC) vectors containing the full-length genomes of several herpesviruses have been used widely
as tools to enable functional studies of viral genes. Marek’s disease viruses (MDVs) are highly oncogenic alphaherpesviruses that
induce rapid-onset T-cell lymphomas in chickens. Oncogenic strains of MDV reconstituted from BAC clones have been used
to examine the role of viral genes in inducing tumours. Past studies have demonstrated continuous increase in virulence of MDV
strains.WehavepreviouslyreportedontheUKisolateC12/130thatshowedincreasedvirulencefeaturesincludinglymphoidorgan
atrophy and enhanced tropism for the central nervous system. Here we report the construction of the BAC clones (pC12/130) of
this strain. Chickens were infected with viruses reconstituted from the pC12/130 clones along with the wild-type virus for the
comparison of the pathogenic properties. Our studies show that BAC-derived viruses induced disease similar to the wild-type
virus, though there were diﬀerences in the levels of pathogenicity between individual viruses. Generation of BAC clones that diﬀer
in the potential to induce cytolytic disease provide the opportunity to identify the molecular determinants of increased virulence
by direct sequence analysis as well as by using reverse genetics approaches on the infectious BAC clones.
1.Introduction
Herpesvirusesaremajorpathogensassociatedwithanumber
of diseases both in man and animals. Since herpesviruses
have large genomes, between 120kbp–230kbp in size, the
manipulation of the viral genomes to identify the molecular
determinants and mechanisms of pathogenesis is diﬃcult.
However, the use of bacterial artiﬁcial chromosome (BAC)
as vectors for cloning the large DNA virus genomes as a
single-copy mini-F plasmid [1]h a so p e n e dn e wa v e n u e sf o r
carrying out reverse genetics approaches for understand-
ing herpesvirus gene functions [2]. Marek’s disease virus
(MDV), a member of the genus Mardivirus, is a highly
contagious alphaherpesvirus that induces Marek’s disease
(MD), characterised predominantly by a rapid-onset T-cell
lymphoma in poultry. BAC technology was ﬁrst applied
to clone the genome of an attenuated serotype 1MDV
strain 584Ap80C [3]. Since then, the genomes of a number
of virulent and attenuated Mardiviruses have been cloned
as infectious BAC clones [4–11] and used to identify the
determinants of virulence as well as for expression of foreign
genes [12–14].
MD is controlled primarily by the widespread use of
a number of live attenuated vaccines since the 1970s.
These include the antigenically related herpesvirus of turkey
(HVT), MDV-2 strain SB-1, as well as the widely used
CVI988 (Rispens) strain [15]. Although vaccines have been
generally very successful in reducing the losses from the
disease, vaccination strategy has not been very eﬀective in
preventing the evolution of viruses towards greater virulence
[16–18]. This has necessitated the periodic introduction of
diﬀerent generations of vaccines to keep up with continuing2 Journal of Biomedicine and Biotechnology
increase in virulence of the MDV and a number of diﬀerent
pathotypes classiﬁed as vMDV, vvMDV, and vv+MDV
pathotypes have been isolated [15, 19]. Even though the
molecular determinants associated with the increasing viru-
lence of these pathotypes are yet to be identiﬁed, the genome
sequence of these viral pathotypes has indicated changes in
parts of their genomes [20, 21]. Although the analysis of the
sequence changes are helpful, functional studies with mutant
viruses are required to identify the determinants of altered
virulence of these MDV pathotypes. Cloning of the genomes
of virulent MDV pathotypes as infectious BAC can facilitate
the application of reverse genetics approaches to generate
mutant viruses and to identify the functional determinants
associated with the altered pathological characteristics of
these viruses.
MDV strain C12/130 was isolated from a ﬁeld out-
break of HVT-vaccinated broilers in 1991 from the United
Kingdom. The disease it produces has an unusually severe
cytolytic phase, with enlargement of spleen, regression of the
primary lymphoid organs, Bursa of Fabricius and thymus,
and very late tumours [22, 23]. Two similar strains were
isolated in Europe at the time, MR36 and MR48 [24];
these strains produced high early mortality and destruction
of the lymphoid tissues [22]. Monocytosis is a feature of
the C12/130 strain, and neurological disease has also been
associatedwithmononuclearcellinﬁltrationofthemeninges
from 6 to10 days post infection. Birds infected with C12/130
strain have increased cell death of the infected B-cells and
macrophages during the acute cytolytic phase [25]. This
virus shares characteristics with vv+MDV as described by
Witter, but cannot be classiﬁed as such due to the lack of
formal pathotyping studies [16].
In the current study, we report on the cloning of the
hypervirulent UK MDV strain C12/130 to elucidate some of
its unique biological properties. Wild-type virus populations
are often considered to exist as a collection of individual
viruses that make up the quasispecies [21, 26], and we
have previously shown that the cloning of the CVI988
(Rispens) virus as BAC clones has enabled the identiﬁcation
of individual clones with molecular diﬀerences in their
genomes [5]. Based on these observations, we hypothesised
that the wild-type C12/130 virus population is comprised of
a pool of viruses, and cloning the genomes of these viruses
as BAC clones would allow us to examine the behaviour of
individual viruses in the pool. This paper describes the in
vitro and in vivo characteristics of viruses derived from ﬁve
individual BAC clones of C12/130 virus.
2.MaterialsandMethods
2.1. Cells and Viruses. Primary or secondary chicken embryo
ﬁbroblasts (CEFs) maintained in Medium 199 (Gibco BRL),
supplemented with 10% Tryptose phosphate broth and
5% foetal calf serum were used to grow up the virus
stocks. C12/130 virus isolated from splenocytes prepared
from infected Rhode Island Red (RIR) chicks at 6 days
postinfection (dpi) were used as the source of DNA for the
generation of the recombinant BAC clones.
2.2. Construction of the BAC Clones. The procedures for the
construction of the BAC clones were carried out essentially
as described [27–29]. Brieﬂy, the pDS-pHA1 vector, which
contains the mini-F plasmid ﬂanked by 2.1 and 3.0kbp
homologous regions surrounding the US2 gene of MDV-
1, was used for the construction of the BAC clones. The
C12/130 viral DNA for the generation of BAC was extracted
from infected CEFs using standard phenol chloroform
extraction methods. Primary CEFs (seeded at 1.3 × 106 cells
perwell)inasixwellplatewereusedforthecotransfectionof
the C12/130 virus-infected DNA and the pDS-pHA1 vector
DNA using the calcium phosphate precipitation method.
Approximately 1.25μg per well of the pDS-pHA1 DNA was
cotransfected with varying volumes (1μL, 2.5μLa n d5μL)
of C12/130 DNA. After cotransfection of the C12-130 DNA
with the pDSpHAI vector, the cells were passaged four times
in selection medium containing mycophenolic acid, xan-
thine, and hypoxanthine. Genomic DNA was then extracted
from the selected cells and electroporated into Ec o l iDH10B
cells. DNA extracts from chloramphenicol-resistant colonies
were further analysed by restriction digestion, followed by
transfection of 1μg of DNA into CEFs, and monitored for
viral infectivity. Of several clones tested, ﬁve clones that
produced MDV plaques on CEFs after transfection of the
BAC DNA were used to prepare viral stocks following two
further passages.
2.3. Analysis of the Recombinant C12/130 BAC DNA. The
integrity of the recombinant BAC constructs was examined
by molecular analyses of the DNA from the individual
C12/130 BAC clones by agarose gel electrophoresis of DNA
samples digested with BamHI, EcoRI, and HindIII. DNA
samples from wild-type C12/130 virus, the ﬁve recombinant
C12/130 BAC clones, and the previously reported pRB-1B5
[27] were also analysed by Southern hybridisation [30]
using Digoxigenin-labelled probes (Roche Diagnostics, East
Sussex, United Kingdom). The DIG-labelled probes speciﬁc
for gpt and Meq genes were prepared by PCR using gpt
probes (5 -ATGAGCGAAAAATACATCGTC-3  and 5 -
TTAGCGACCGGAGATTGGCGG-3 ) and the meq probes
(5 -GCACTCTAGAGGTGTAAAGAGATGTCTCAG-3  and
5 -TAACTCGAGGAGAAGAAACATGGGGCATAG-3 ),
respectively.
2.4. Animal Experiments. All chickens used in the experi-
m e n t sw e r es p e c i ﬁ cp a t h o g e nf r e e( S P F ) ,f r e eo fm a t e r n a l
antibodies to MDV, and hatched and reared in the Experi-
mental Animal House with HEPA ﬁltered rooms, one group
per room. All the experiments were carried out under British
Home Oﬃce regulations, by trained staﬀ holding a Home
Oﬃce Personal Licence for the various procedures. Birds
were killed by a schedule I method once the clinical end-
point deﬁned by Home Oﬃce regulations was reached.
Experiment 1 was designed to examine the genetic
susceptibility of diﬀerent lines of chickens to infection with
wild-type C12/130 virus. The ﬁve lines of chickens used in
this experiment included the congenic inbred line N (MHC
B21/21), line P (MHC B19/19), line 6, line 7 (MHC B2/2), andJournal of Biomedicine and Biotechnology 3
the outbred Rhode Island Red (RIR) line. Ten birds of each
line were infected with 1,000 plaque forming units (pfu)
of wild-type C12/130 virus stocks via the intra-abdominal
route at one day of age and observed for 60 days for the
development of clinical signs. Birds that developed clinical
signs during or at the end of the experiment were examined
post mortem for gross or histopathological lesions.
Experiment 2 was designed to examine the diﬀerences
between the recombinant viruses reconstituted from the
individualBACclonesintheirabilitytoinduceearlycytolytic
disease. The experiment was carried out in one-day-old
outbred RIR chickens inoculated with 1,000pfu of wild-
type C12/130, and the reconstituted recombinant viruses as
described in Experiment 1, 12 per group, each was housed
in separate rooms with two sentinels. The cytolytic phase
of infection was allowed to proceed, and the birds were
observed for 12 days. All the birds that developed clinical
signs and reached the clinical endpoint (birds that appeared
distressed, that is, oﬀ their legs, not eating or drinking, with
paralysis, twisted neck, or visible tumours) were killed, and
the survival rates calculated from the incidence of MD based
on gross or histopathological lesions with GraphPad Prism
(Version 5) using the product limit method of Kaplan and
Meier, and curves were compared using the log rank test,
equivalent to the Mantel-Cox test [31].
2.5. Immunoﬂuorescence Detection of Viral Antigens in
Infected Tissues. Tissues were taken from freshly killed birds
and ﬁxed in 4% paraformaldehyde for two hours then trans-
ferredtoPBSat4◦C.Tissuesectionswerecutat70μmusinga
VT1000S vibrating microtome (Leica Microsystems, Milton
Keynes, United Kingdom). Sections were permeabilised in
0.1%TritonX100(Sigma)foronehouratroomtemperature
andblockedovernightinblockingbuﬀer(PBSsupplemented
with 0.05% sodium azide, 0.5% bovine serum albumin,
and PBS/BSA). Sections were incubated with primary mon-
oclonal antibody BD1 recognising MDV-encoded protein
pp38 [32] and species-speciﬁc Alexa Fluor 568-conjugated
secondary antibodies. The sections were washed in PBS
and cellular nuclei stained with DAPI (1:5,000) for 40
minutes. The sections were mounted onto glass slides using




3.1. Cloning of the Genomes of Hypervirulent C12/130 MDV
as Infectious BAC Clones. Cotransfection of CEFs with wild-
type C12/130 viral DNA and the pDS-pHA1 DNA and sub-
sequent growth in the presence of selection medium showed
evidence of viral infection, demonstrating the growth of
recombinant viruses. Electroporation of the DNA extracted
from the CEFs into E. coli DH10B cells generated a number
of chloramphenicol-resistant colonies. The ability of the
high molecular weight DNA prepared from these cultures to
reconstitute infectious virus was tested by DNA transfection
into CEFs. These experiments showed that ﬁve of the DNA
extracts were able to produce infectious virus 3-4 days after
transfection, demonstrating the reconstitution of the virus
from the transfected DNA. The size and morphology of
the plaques produced by the wild-type and the recombi-
nant C12/130 were indistinguishable (not shown). These
infectious BAC clones were designated pC12/130-3, -5, -8,
-10, and -15, respectively. Pulse ﬁeld gel electrophoresis
of the BamHI, EcoRI, and HindIII digested DNA samples
from these clones demonstrated a pattern similar to that
of the pRB-1B5 clone (data not shown), demonstrating
that the BAC clones did not have any major deletions or
genomic rearrangements. This further demonstrated the
infectivity of these clones. Southern blot hybridization of
the EcoRI-digested DNA of these clones with the gpt probe
demonstrated a single major hybridizing band (∼1.7kb) in
all the pC12/130 clones, at an identical position to that in the
pRB-1B5 (Figure 1(a)). Demonstration of identical bands
in the DNA samples from the reconstituted viruses of two
of the BAC clones, that is, pC12/130-10 and pC12/130-15,
showed that the mini-F plasmid is carried in the genome of
the reconstituted viruses. The speciﬁcity of the probe was
conﬁrmed by the absence of signals in the DNA prepared
from the wild-type C12/130 virus. Hybridization of the same
blot with the Meq probe detected the meq gene (∼2.2kb)
in all the BAC clones and the wild-type and reconstituted
C12/130 viruses (Figure 1(b)).
3.2. Dynamics of C12/130 Virus Infection in Diﬀerent Genetic
Lines. One of the distinguishing features of some of the
recent hypervirulent MDV strains, such as the C12/130
strain, is the ability to induce rapid-onset cytolytic disease
characterized by marked atrophy of the lymphoid organs
and high mortality [33]. Previous studies have also shown
that birds infected with C12/130 virus developed marked
monocytosis and inﬁltration into the brain [34–36], possibly
accounting for the high levels of mortality. Interestingly, the
involvement of the brain has been shown to be associated
with a number of the hypervirulent strains [37, 38]. The
association between occurrences of neurological syndromes
and the increasing virulence of MDV strains has led to the
demonstration that neuropathotyping can be used to classify
the virulence of MDV pathotypes [39]. In the present study,
we ﬁrst examined whether the wild-type C12/130 virus did
indeedinduceacutecytolyticdiseaseandneurologicalsymp-
toms and whether the genetic background of the chickens
aﬀected the susceptibility to the disease. The incidence of the
disease, calculated from the percent survival during the 60-
day experimental period, showed that the outbred RIR birds
were highly susceptible to the disease, with more than 90 per
cent of the birds developing acute cytolytic disease within
the ﬁrst 10 days after infection (Figure 2(a)). The study of
geneticallysusceptiblelinePandline7demonstratedaround
40% incidence of MD during the same period, with the latter
showing high incidence of the disease towards the end of the
experimental period. The two genetically resistant lines N
and 6 displayed only mild levels of MD, demonstrating that
thegeneticresistancemechanismsoftheselinesalsofunction






Figure 1: Southern hybridisation of wild-type and BAC clones of
C12/130. Southern blots of the EcoRI-digested DNA from the wild-
typeC12/130virusandtheBACclonessequentiallyhybridizedwith
digoxigenin-labelled(a)gpt and(b)meqprobe.Whilethegpt probe
detects the speciﬁc band in all BAC-derived viral DNA, but not in
the wild-type C12/130 virus, meq probe gives positive signals in all
the lanes. Band sizes are shown on the right hand side. Lanes (1)
pRB-1B5 [4], (2) pC12-130-3, (3) pC12-130-5, (4) pC12-130-8, (5)
pC12-130-10, (6) pC12-130-15, (7) wild-type C12-130, (8) virus
derived from pC12-130-10, and (9) pC12-130-15.
3.3. BAC-Derived C12/130 Viruses Can Induce Cytolytic
Disease. Having demonstrated that the RIR chicks are
highly susceptible to the early cytolytic disease induced
by C12/130 virus, we wanted to examine whether the
recombinant C12/130 viruses reconstituted from the indi-
vidual infectious BAC clones induced cytolytic disease and
neurological lesions akin to the wild-type virus from which
they were derived. For this, we carried out experimental
infection of highly susceptible one-day-old RIR chickens
with C12/130 viruses reconstituted from ﬁve infectious BAC
clones together with the wild-type virus. Groups of birds
infected with 1,000pfu of each of the viruses were observed
during the 12-day experimental period for the development
of cytolytic disease. As demonstrated in the previous exper-
iment, more than 90 per cent of the birds infected with
the wild-type C12/130 virus developed the early cytolytic
disease during this period (Figure 2(b)). However, viruses
reconstituted from the ﬁve individual BAC clones presented
ar a n g eo fd i ﬀerences in early cytolytic disease development.
C12/130 virus reconstituted from the BAC clone 10 induced
the highest level of the disease in more than 50 per cent
of the birds, with viruses from the clones -3, -5, and -8
developing slightly lower levels of the disease. In contrast,
virus derived from the pC12/130-15 clone did not produce
any disease during the experimental period (Figure 2(b)).
The clinical signs of birds developing acute cytolytic disease
were indistinguishable between wild-type and reconstituted
viruses and included ruﬄed feathers, crouched appearance,
and neurological signs. As expected, none of the birds had
any evidence of tumors although varying levels of atrophy
of the lymphoid organs thymus and bursa of Fabricius were
visible in many of the birds that developed the cytolytic
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Figure 2: Survival curves of birds infected with C12/130 viruses.
Cumulative percentage of survival of (a) genetically distinct
lines of birds challenged with wild-type C12/130 virus during
the 60-day experimental period (n = 10), and (b) RIR chicks
infected with wild-type C12/130 virus and the reconstituted viruses
from pC12/130-3, pC12/130-5, pC12/130-8, pC12/130-10, and
pC12/130-15 during the 12-day experimental period (n = 12).
by qPCR from 14 days after infection of their cohorts;
only those housed with the wild-type infected birds became
infected with MD (data not shown).
3.4. Detection of Viral Antigen in the Brain of C12/130 Virus-
Infected Birds. Previously, we have reported the detection
of viral antigens in brain lesions of birds infected with
C121/30 virus [35]. Similar reports on the detection of virus-
infected cells have also been published in birds infected with
vv+MDV strains such as 648A [40], suggesting that the inﬁl-
tration of virus-infected cells into the brain is a characteristic




Figure 3: Confocal immunoﬂuorescence images of brain tissues
stained with MDV pp38-speciﬁc monoclonal antibody BD1. Brain
tissues from birds infected with (a) wild-type C12/130, (b)
pC12/130-10, and (c) pC12/130-15 viruses. The brain tissues were
taken eight days postinfection showing infected cells stained with
pp38- (red) and DAPI- (blue) stained nuclei.
whether the C12/130 viruses reconstituted from the BAC
clones would inﬁltrate the brain of birds and express viral
antigens. For this, we examined the brain samples from birds
infected with the wild-type C12/130 or the viruses recon-
stituted from the pC12/130-10 and pC12/130-15 clones for
viralantigenpp38byimmunoﬂuorescencestainingusingthe
speciﬁc antibody BD1. Viral antigen pp38 could be detected
in the brain tissues of birds infected with the wild-type as
well as the two BAC-derived viruses (Figure 3). Interestingly,
pp38 was also detected in the brain of birds infected with
C12/130-15 virus although they did not develop any early
cytolytic disease. These results suggested that the inﬁltration
of infected cells is not necessarily associated with the acute
cytolytic disease although we did not attempt to quantitate
the levels of the inﬁltration of infected cells into the brain.
Our study presents several interesting highlights. At the
outset, this is the ﬁrst report on the cloning of the full-
length genome of a hypervirulent European MDV isolate
as infectious BAC clones. Moreover, induction of cytolytic
disease by some of the BAC-derived viruses demonstrates
that the cloned viruses retain the biological characteristics
of the parent virus. Interestingly, the study also showed
that no viruses from any of the individual clones were
able to induce the disease to the same levels as the wild-
type virus. Similar observations have also been made with
BAC clones of oncogenic MDV strains such as RB-1B [4].
Such diﬀerences may be due to the quasispecies nature
[20, 21] that could provide selective ﬁtness advantages for
more virulent strains in the wild-type virus. Alternatively,
the cloning steps involved in the construction of the BAC
may selectively disadvantage the more virulent viruses in the
pool. Our study shows that individual viral genomes, despite
originating from a single population of parental virus, can
diﬀer in virulence in disease models. In fact, the isolation
of BAC clones pC12/130-10 and pC12/130-15 that behave
at either end of the disease spectrum, with respect to the
induction of early cytolytic disease and mortality, provides
a great opportunity to identify the molecular virulence
determinants by direct sequence analysis as well as by the
application of reverse genetics.
4. Conclusions
We report here the cloning of the full-length genome of a
hypervirulent UK MDV strain C12/130 that induces acute
cytolytic disease with brain lesions. The ability of these
infectious BAC clones to reconstitute viruses that have very
similar biological characteristics to the parent wild-type
virus provides the opportunity to carry out investigations
into the identiﬁcation of molecular determinants associated
with the distinct features of this hypervirulent strain to
induce acute cytolytic disease. We also show that diﬀerent
BAC clones that represent individual genomes of viruses,
despiteoriginatingfromasinglesource,diﬀeredinvirulence.
The construction of BAC clones of these important viral
pathogens that diﬀer in virulence oﬀers the opportunity to
identify viral determinants associated with acute cytolytic
disease and neuronal pathogenicity.
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